<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628949</url>
  </required_header>
  <id_info>
    <org_study_id>CIS-018</org_study_id>
    <nct_id>NCT04628949</nct_id>
  </id_info>
  <brief_title>A Single-Use Duodenoscope in a Real-World Setting</brief_title>
  <official_title>A Single-Use Duodenoscope in a Real-World Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ambu A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ambu Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infinite Clinical Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prelude Dynamics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ambu A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess how the aScope™ Duodeno endoscope performs in procedures that treat&#xD;
      problems of the bile and pancreatic ducts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, single-arm post-market observational clinical study&#xD;
      that will assess the single-use Ambu® aScope™ Duodeno for non-emergent, standard of care&#xD;
      (SOC) ERCP procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, Non-Randomized, Single-Arm, Post-Market Observational Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the ERCP procedural success rates with the aScope™ Duodeno endoscope when completing the ERCP procedure for the intended indication(s).</measure>
    <time_frame>Procedure Completion (Day 0)</time_frame>
    <description>Procedure success will be defined as the successful completion of the ERCP procedure with the aScope™ Duodeno endoscope. The procedural success rate will be the incidence rate of success for the ERCP procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish comprehensive performance attributes of aScope™ Duodeno endoscope through its use by multiple endoscopists in conducting various ERCP procedures.</measure>
    <time_frame>Procedure Completion (Day 0)</time_frame>
    <description>Procedure success for sub categories of ERCP procedures will be defined as the successful completion of the ERCP procedure with the aScope™ Duodeno endoscope. The procedural success rate will be the incidence rate of success for the stratified sub-categories of ERCP procedures with the the aScope™ Duodeno endoscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate rate of conversion to a reusable endoscope, other endoscope or an open procedure from the aScope™ Duodeno endoscope during the ERCP procedure.</measure>
    <time_frame>Procedure Completion (Day 0)</time_frame>
    <description>Rate of conversion will be measured by the incidence rate of when a conversion to a different endoscope or open procedure is necessitated during the ERCP procedure with the aScope™ Duodeno endoscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate rate of successful completion of a converted ERCP procedure.</measure>
    <time_frame>Procedure Completion (Day 0)</time_frame>
    <description>Successful completion will be measured by the incidence rate of success for converted ERCP procedure as stratified by the conversion method (reusable scope, other endoscope, other procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the device deficiency rate for the aScope™ Duodeno endoscope.</measure>
    <time_frame>Procedure Completion (Day 0)</time_frame>
    <description>Incidence rate of device deficiencies as defined as either a device failure or device malfunction for the aScope™ Duodeno endoscope during ERCP procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate physician satisfaction with the aScope™ Duodeno endoscope.</measure>
    <time_frame>Procedure Completion (Day 0)</time_frame>
    <description>Physician reported outcomes questionnaire on physician satisfaction with the aScope™ Duodeno endoscope for ERCP procedures.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate safety of the aScope™ Duodeno endoscope in ERCP.</measure>
    <time_frame>Day 30 (+3) Post-Procedure</time_frame>
    <description>Safety will be assessed based on the incidence rates of adverse events based on the seriousness and relatedness to the device and/or procedure.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Endoscopic Retrograde Cholangiopancreatography (ERCP)</condition>
  <arm_group>
    <arm_group_label>aScope™ Duodeno endoscope and aBox™ Duodeno</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects who are undergoing non-emergent, clinically indicated ERCP using aScope™ Duodeno endoscope and aBox™ Duodeno.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>aScope™ Duodeno endoscope and aBox™ Duodeno</intervention_name>
    <description>The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.&#xD;
The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope.</description>
    <arm_group_label>aScope™ Duodeno endoscope and aBox™ Duodeno</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥ 18 years old.&#xD;
&#xD;
          2. Subject is indicated and scheduled for an elective, non-emergent ERCP.&#xD;
&#xD;
          3. Subject is willing and able to give informed consent and HIPAA authorization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has altered pancreaticobiliary anatomy including:&#xD;
&#xD;
               1. Billroth II&#xD;
&#xD;
               2. Roux-en-Y gastric bypass&#xD;
&#xD;
               3. Loop gastric bypass&#xD;
&#xD;
               4. Post-Whipple&#xD;
&#xD;
               5. Roux-en-Y hepaticojejunostomy&#xD;
&#xD;
          2. Subject requires an emergency ERCP (emergent decompression procedure within 6-12 hours&#xD;
             of presentation to prevent life-threatening sequelae).&#xD;
&#xD;
          3. Subject has any of the following severe co-morbid conditions&#xD;
&#xD;
               1. Morbid obesity (BMI ≥ 40)&#xD;
&#xD;
               2. Unstable cardiopulmonary conditions&#xD;
&#xD;
               3. Severe and uncorrectable coagulopathy&#xD;
&#xD;
               4. Severe and uncorrectable thrombocytopenia&#xD;
&#xD;
          4. Subject has clinically significant esophageal, pyloric or duodenal strictures.&#xD;
&#xD;
          5. Subject is pregnant or female with reproductive capability who is unwilling to have a&#xD;
             pre-procedure pregnancy test and use birth control.&#xD;
&#xD;
          6. Subject is actively taking an anticoagulant or antiplatelet agent other than aspirin.&#xD;
&#xD;
          7. Subject, in the opinion of the Investigator, has a severe comorbidity, poor general&#xD;
             physical/mental health and/or a condition that will not allow the subject to be a good&#xD;
             study candidate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Smith</last_name>
    <role>Study Director</role>
    <affiliation>Ambu Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Smith</last_name>
    <phone>+1 410 980 2356</phone>
    <email>elsm@ambu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trine Højgaard Tølbøll</last_name>
    <phone>+45 2543 7978</phone>
    <email>trht@ambu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Frazier, BSN, RN</last_name>
      <phone>205-975-9564</phone>
      <email>thomasfrazier@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Kondol Kyanam Kabir Baig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Miley</last_name>
      <phone>303-724-9228</phone>
      <email>Angelina.Miley@CUANSCHUTZ.EDU</email>
    </contact>
    <investigator>
      <last_name>Sachin Wani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Gastroenterology</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Alles, PA-C</last_name>
      <email>leahalles03@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kamran Ayub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University, University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzette Schmidt, RN, BSN, CCRP</last_name>
      <phone>317-278-0691</phone>
      <email>suschmid@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart Sherman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Hyland</last_name>
      <phone>507-284-4723</phone>
      <email>Hyland.Erik@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Petersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Grossman School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghoncheh Ghiasian, MPH</last_name>
      <phone>646-501-7822</phone>
      <email>Ghoncheh.Ghiasian@NYULangone.org</email>
    </contact>
    <investigator>
      <last_name>Adam Goodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai South Nassau</name>
      <address>
        <city>Oceanside</city>
        <state>New York</state>
        <zip>11572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Surillo, MHA</last_name>
      <phone>516-632-3312</phone>
      <email>evelyn.surillo@snch.org</email>
    </contact>
    <investigator>
      <last_name>Frank Gress, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Schneider</last_name>
      <phone>216-444-1122</phone>
      <phone_ext>4-1122</phone_ext>
      <email>schneie3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>John Vargo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa O Balonwu</last_name>
      <phone>713-798-2308</phone>
      <email>Vanessa.Balonwu@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamed Othman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Domagk D, Oppong KW, Aabakken L, Czakó L, Gyökeres T, Manes G, Meier P, Poley JW, Ponchon T, Tringali A, Bellisario C, Minozzi S, Senore C, Bennett C, Bretthauer M, Hassan C, Kaminski MF, Dinis-Ribeiro M, Rees CJ, Spada C, Valori R, Bisschops R, Rutter MD. Performance measures for endoscopic retrograde cholangiopancreatography and endoscopic ultrasound: A European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. United European Gastroenterol J. 2018 Dec;6(10):1448-1460. doi: 10.1177/2050640618808157. Epub 2018 Oct 19. Review.</citation>
    <PMID>30574315</PMID>
  </reference>
  <reference>
    <citation>Baron, Kozarek, Carr-Locke, et al. ERCP 3rd Edition. Elsevier. 2019.</citation>
  </reference>
  <reference>
    <citation>Lee DH, Kim DB, Kim HY, Baek HS, Kwon SY, Lee MH, Park JC. Increasing potential risks of contamination from repetitive use of endoscope. Am J Infect Control. 2015 May 1;43(5):e13-7. doi: 10.1016/j.ajic.2015.01.017. Epub 2015 Feb 25.</citation>
    <PMID>25726130</PMID>
  </reference>
  <reference>
    <citation>Alfa MJ, Olson N, DeGagne P, Jackson M. A survey of reprocessing methods, residual viable bioburden, and soil levels in patient-ready endoscopic retrograde choliangiopancreatography duodenoscopes used in Canadian centers. Infect Control Hosp Epidemiol. 2002 Apr;23(4):198-206.</citation>
    <PMID>12002234</PMID>
  </reference>
  <reference>
    <citation>Petersen BT. Duodenoscope reprocessing: risk and options coming into view. Gastrointest Endosc. 2015 Sep;82(3):484-7. doi: 10.1016/j.gie.2015.07.004.</citation>
    <PMID>26279349</PMID>
  </reference>
  <reference>
    <citation>Ross AS, Baliga C, Verma P, Duchin J, Gluck M. A quarantine process for the resolution of duodenoscope-associated transmission of multidrug-resistant Escherichia coli. Gastrointest Endosc. 2015 Sep;82(3):477-83. doi: 10.1016/j.gie.2015.04.036. Epub 2015 Jun 16.</citation>
    <PMID>26092616</PMID>
  </reference>
  <reference>
    <citation>USA FDA: Medical Device Safety: Safety Communications. The FDA Continues to Remind Facilities of the Importance of Following Duodenoscope Reprocessing Instructions: FDA Safety Communication. 12 April 2019.</citation>
  </reference>
  <reference>
    <citation>USA FDA: Medical Device Safety: Safety Communications. The FDA is Recommending Transition to Duodenoscopes with Innovative Designs to Enhance Safety: FDA Safety Communication. 29 August 2019.</citation>
  </reference>
  <reference>
    <citation>Balan GG, Rosca I, Ursu EL, Fifere A, Varganici CD, Doroftei F, Turin-Moleavin IA, Sandru V, Constantinescu G, Timofte D, Stefanescu G, Trifan A, Sfarti CV. Duodenoscope-Associated Infections beyond the Elevator Channel: Alternative Causes for Difficult Reprocessing. Molecules. 2019 Jun 25;24(12). pii: E2343. doi: 10.3390/molecules24122343.</citation>
    <PMID>31242689</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Eisen G, Romagnuolo J, Vargo J, Baron T, Tarnasky P, Schutz S, Jacobson B, Bott C, Petersen B. Grading the complexity of endoscopic procedures: results of an ASGE working party. Gastrointest Endosc. 2011 May;73(5):868-74. doi: 10.1016/j.gie.2010.12.036. Epub 2011 Mar 5.</citation>
    <PMID>21377673</PMID>
  </reference>
  <reference>
    <citation>Dumonceau JM, Kapral C, Aabakken L, Papanikolaou IS, Tringali A, Vanbiervliet G, Beyna T, Dinis-Ribeiro M, Hritz I, Mariani A, Paspatis G, Radaelli F, Lakhtakia S, Veitch AM, van Hooft JE. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020 Feb;52(2):127-149. doi: 10.1055/a-1075-4080. Epub 2019 Dec 20.</citation>
    <PMID>31863440</PMID>
  </reference>
  <reference>
    <citation>ASGE Standards of Practice Committee, Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, Bruining DH, Eloubeidi MA, Fanelli RD, Faulx AL, Gurudu SR, Kothari S, Lightdale JR, Qumseya BJ, Shaukat A, Wang A, Wani SB, Yang J, DeWitt JM. Adverse events associated with ERCP. Gastrointest Endosc. 2017 Jan;85(1):32-47. doi: 10.1016/j.gie.2016.06.051. Epub 2016 Aug 18. Review.</citation>
    <PMID>27546389</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endoscopic Retrograde Cholangiopancreatography</keyword>
  <keyword>ERCP</keyword>
  <keyword>Duodenoscope</keyword>
  <keyword>Endoscope</keyword>
  <keyword>aScope Duodeno</keyword>
  <keyword>aBox</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

